EU regulators back Novartis inhaler, Gilead HIV drug
LONDON, July 26
LONDON, July 26 (Reuters) - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Washington state teen shooter's family living in 'nightmare'
- Suspect in two California deputy deaths charged with murder, carjacking
- Iraqi security forces and Kurds gain ground against Islamic State
- Police seek motive in fatal Washington state school shooting